These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

375 related articles for article (PubMed ID: 29743589)

  • 1. Dual inhibition of BCL-XL and MCL-1 is required to induce tumour regression in lung squamous cell carcinomas sensitive to FGFR inhibition.
    Weeden CE; Ah-Cann C; Holik AZ; Pasquet J; Garnier JM; Merino D; Lessene G; Asselin-Labat ML
    Oncogene; 2018 Aug; 37(32):4475-4488. PubMed ID: 29743589
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Fibroblast growth factor receptor inhibitor erdafitinib promotes Mcl-1 degradation and synergistically induces apoptosis with Bcl-xL/Bcl-2 inhibitor in urothelial cancer cells.
    Ohtsu A; Arai S; Sawada T; Kato M; Maeno Y; Miyazawa Y; Fujizuka Y; Sekine Y; Koike H; Matsui H; Suzuki K
    Biochem Biophys Res Commun; 2022 Nov; 628():76-83. PubMed ID: 36084554
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Assessment of ABT-263 activity across a cancer cell line collection leads to a potent combination therapy for small-cell lung cancer.
    Faber AC; Farago AF; Costa C; Dastur A; Gomez-Caraballo M; Robbins R; Wagner BL; Rideout WM; Jakubik CT; Ham J; Edelman EJ; Ebi H; Yeo AT; Hata AN; Song Y; Patel NU; March RJ; Tam AT; Milano RJ; Boisvert JL; Hicks MA; Elmiligy S; Malstrom SE; Rivera MN; Harada H; Windle BE; Ramaswamy S; Benes CH; Jacks T; Engelman JA
    Proc Natl Acad Sci U S A; 2015 Mar; 112(11):E1288-96. PubMed ID: 25737542
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cisplatin Increases Sensitivity to FGFR Inhibition in Patient-Derived Xenograft Models of Lung Squamous Cell Carcinoma.
    Weeden CE; Holik AZ; Young RJ; Ma SB; Garnier JM; Fox SB; Antippa P; Irving LB; Steinfort DP; Wright GM; Russell PA; Ritchie ME; Burns CJ; Solomon B; Asselin-Labat ML
    Mol Cancer Ther; 2017 Aug; 16(8):1610-1622. PubMed ID: 28611104
    [TBL] [Abstract][Full Text] [Related]  

  • 5. BM-1197: a novel and specific Bcl-2/Bcl-xL inhibitor inducing complete and long-lasting tumor regression in vivo.
    Bai L; Chen J; McEachern D; Liu L; Zhou H; Aguilar A; Wang S
    PLoS One; 2014; 9(6):e99404. PubMed ID: 24901320
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Mcl-1 is an important therapeutic target for oral squamous cell carcinomas.
    Maji S; Samal SK; Pattanaik L; Panda S; Quinn BA; Das SK; Sarkar D; Pellecchia M; Fisher PB; Dash R
    Oncotarget; 2015 Jun; 6(18):16623-37. PubMed ID: 26009874
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Targeting the differential addiction to anti-apoptotic BCL-2 family for cancer therapy.
    Inoue-Yamauchi A; Jeng PS; Kim K; Chen HC; Han S; Ganesan YT; Ishizawa K; Jebiwott S; Dong Y; Pietanza MC; Hellmann MD; Kris MG; Hsieh JJ; Cheng EH
    Nat Commun; 2017 Jul; 8():16078. PubMed ID: 28714472
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The novel BH3 α-helix mimetic JY-1-106 induces apoptosis in a subset of cancer cells (lung cancer, colon cancer and mesothelioma) by disrupting Bcl-xL and Mcl-1 protein-protein interactions with Bak.
    Cao X; Yap JL; Newell-Rogers MK; Peddaboina C; Jiang W; Papaconstantinou HT; Jupitor D; Rai A; Jung KY; Tubin RP; Yu W; Vanommeslaeghe K; Wilder PT; MacKerell AD; Fletcher S; Smythe RW
    Mol Cancer; 2013 May; 12(1):42. PubMed ID: 23680104
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Design, synthesis and evaluation of marinopyrrole derivatives as selective inhibitors of Mcl-1 binding to pro-apoptotic Bim and dual Mcl-1/Bcl-xL inhibitors.
    Li R; Cheng C; Balasis ME; Liu Y; Garner TP; Daniel KG; Li J; Qin Y; Gavathiotis E; Sebti SM
    Eur J Med Chem; 2015 Jan; 90():315-331. PubMed ID: 25437618
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Potent efficacy of MCL-1 inhibitor-based therapies in preclinical models of mantle cell lymphoma.
    Dengler MA; Teh CE; Thijssen R; Gangoda L; Lan P; Herold MJ; Gray DH; Kelly GL; Roberts AW; Adams JM
    Oncogene; 2020 Feb; 39(9):2009-2023. PubMed ID: 31772331
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Functional disparities among BCL-2 members in tonsillar and leukemic B-cell subsets assessed by BH3-mimetic profiling.
    Peperzak V; Slinger E; Ter Burg J; Eldering E
    Cell Death Differ; 2017 Jan; 24(1):111-119. PubMed ID: 27689871
    [TBL] [Abstract][Full Text] [Related]  

  • 12. XPO1 inhibitor KPT-330 synergizes with Bcl-xL inhibitor to induce cancer cell apoptosis by perturbing rRNA processing and Mcl-1 protein synthesis.
    Zhu ZC; Liu JW; Yang C; Zhao M; Xiong ZQ
    Cell Death Dis; 2019 May; 10(6):395. PubMed ID: 31113936
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Exploiting MCL1 Dependency with Combination MEK + MCL1 Inhibitors Leads to Induction of Apoptosis and Tumor Regression in
    Nangia V; Siddiqui FM; Caenepeel S; Timonina D; Bilton SJ; Phan N; Gomez-Caraballo M; Archibald HL; Li C; Fraser C; Rigas D; Vajda K; Ferris LA; Lanuti M; Wright CD; Raskin KA; Cahill DP; Shin JH; Keyes C; Sequist LV; Piotrowska Z; Farago AF; Azzoli CG; Gainor JF; Sarosiek KA; Brown SP; Coxon A; Benes CH; Hughes PE; Hata AN
    Cancer Discov; 2018 Dec; 8(12):1598-1613. PubMed ID: 30254092
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Co-active receptor tyrosine kinases mitigate the effect of FGFR inhibitors in FGFR1-amplified lung cancers with low FGFR1 protein expression.
    Kotani H; Ebi H; Kitai H; Nanjo S; Kita K; Huynh TG; Ooi A; Faber AC; Mino-Kenudson M; Yano S
    Oncogene; 2016 Jul; 35(27):3587-97. PubMed ID: 26549034
    [TBL] [Abstract][Full Text] [Related]  

  • 15. BH3-only proteins are dispensable for apoptosis induced by pharmacological inhibition of both MCL-1 and BCL-X
    Greaves G; Milani M; Butterworth M; Carter RJ; Byrne DP; Eyers PA; Luo X; Cohen GM; Varadarajan S
    Cell Death Differ; 2019 Jun; 26(6):1037-1047. PubMed ID: 30185825
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Hypertonicity counteracts MCL-1 and renders BCL-XL a synthetic lethal target in head and neck cancer.
    Heimer S; Knoll G; Neubert P; Hammer KP; Wagner S; Bauer RJ; Jantsch J; Ehrenschwender M
    FEBS J; 2021 Mar; 288(6):1822-1838. PubMed ID: 32710568
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Key Survival Factor, Mcl-1, Correlates with Sensitivity to Combined Bcl-2/Bcl-xL Blockade.
    Williams MM; Lee L; Hicks DJ; Joly MM; Elion D; Rahman B; McKernan C; Sanchez V; Balko JM; Stricker T; Estrada MV; Cook RS
    Mol Cancer Res; 2017 Mar; 15(3):259-268. PubMed ID: 28039357
    [TBL] [Abstract][Full Text] [Related]  

  • 18. PI3K/mTOR dual inhibitor NVP-BEZ235 decreases Mcl-1 expression and sensitizes ovarian carcinoma cells to Bcl-xL-targeting strategies, provided that Bim expression is induced.
    Jebahi A; Villedieu M; Pétigny-Lechartier C; Brotin E; Louis MH; Abeilard E; Giffard F; Guercio M; Briand M; Gauduchon P; Lheureux S; Poulain L
    Cancer Lett; 2014 Jun; 348(1-2):38-49. PubMed ID: 24650799
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The Bcl-xL inhibitor, ABT-737, efficiently induces apoptosis and suppresses growth of hepatoma cells in combination with sorafenib.
    Hikita H; Takehara T; Shimizu S; Kodama T; Shigekawa M; Iwase K; Hosui A; Miyagi T; Tatsumi T; Ishida H; Li W; Kanto T; Hiramatsu N; Hayashi N
    Hepatology; 2010 Oct; 52(4):1310-21. PubMed ID: 20799354
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Combined inhibition of aurora kinases and Bcl-xL induces apoptosis through select BH3-only proteins.
    Li J; Chen CH; O'Neill KL; Fousek-Schuller VJ; Black AR; Black JD; Zhang J; Luo X
    J Biol Chem; 2023 Feb; 299(2):102875. PubMed ID: 36621626
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.